Jakub Dyczko

Jakub Dyczko

Auto-generated profile, based on publicly available information

Jakub Dyczko

4th Military Clinical Hospital with Polyclinic SP ZOZ in Wroclaw, Rudolfa Weigla 5, 50-985 Wrocław, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
AWAmadea Wrzesinska
Amadea Wrzesinska
MKMateusz Korowacki
Mateusz Korowacki
IRIga Rusin
Iga Rusin
KKKarol Kazimierczak
Karol Kazimierczak
KMKrystian Mączka
Krystian Mączka
DGDaniel Grobecki
Daniel Grobecki
Introduction: Achilles tendon tendinopathy is a common degenerative disorder causing pain and functional limitation. Despite numerous treatment options, optimal management remains a clinical challenge. Aim: To summarize current evidence on the pathophysiology, diagnosis, conservative treatment, modern adjunctive therapies, and surgical management of Achilles tendon tendinopathy . Materials and methods: This narrative review is based on scientific literature, including guidelines, systematic reviews, and clinical studies. Particular attention was paid to diagnostic methods, progressive rehabilitation, extracorporeal shockwave therapy (ESWT), injections (PRP, hyaluronic acid, high-volume), fenestration, stem cells, and surgery. Results: Diagnosis is primarily clinical, with ultrasound and MRI reserved for unclear or resistant cases. Conservative treatment is the first-line approach, focusing on load management and structured rehabilitation (e.g., the Alfredson protocol). Modern adjunctive therapies and injections may provide benefits, though evidence quality varies. Surgical treatment is reserved for persistent cases failing conservative therapy. Conclusions: Effective management requires an individualized, multidisciplinary approach centered on patient education, load modification, and evidence-based rehabilitation. Biological and minimally invasive therapies serve as adjuncts, but further high-quality studies are needed

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JDJakub Dyczko
Jakub Dyczko
FKFilip Kruczek
Filip Kruczek
KMKrystian Mączka
Krystian Mączka
DGDaniel Grobecki
Daniel Grobecki
BŚBartosz Świrad
Bartosz Świrad
MPMichał Przybylski
Michał Przybylski
Background. Familial hypercholesterolemia (FH) is a common autosomal dominant genetic disorder associated with premature atherosclerotic cardiovascular disease. Despite established international guidelines, FH remains substantially underdiagnosed, particularly in young adults. Aim. This narrative review summarizes current evidence on diagnostic challenges and barriers to guideline implementation in this population. Methods. A narrative literature review was conducted using PubMed/MEDLINE, Scopus, and Web of Science databases. The review focused on evidence regarding FH epidemiology, diagnostic approaches, genetic testing, cascade screening, treatment strategies, and implementation gaps in young adults. Results. Registry data indicate that the median age of FH diagnosis is 44.4 years, suggesting delayed identification and prolonged exposure to elevated low-density lipoprotein cholesterol levels during early adulthood. In young adults, diagnosis is often limited by the absence of overt clinical signs, reducing the utility of clinical scoring systems such as the Dutch Lipid Clinic Network criteria. As a result, diagnosis relies primarily on lipid measurements, family history, and genetic testing. However, genetic testing and cascade screening remain underutilized in routine clinical practice. Conclusions. A persistent gap exists between guideline recommendations and real-world management of FH. Delayed diagnosis and suboptimal implementation of treatment strategies contribute to inadequate cardiovascular risk reduction in young adults. Improving early detection through enhanced use of genetic testing, optimization of cascade screening, and timely initiation of lipid-lowering therapy may reduce cumulative LDL-C exposure and improve long-term cardiovascular outcomes.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MKMateusz Korowacki
Mateusz Korowacki
AWAmadea Wrzesińska
Amadea Wrzesińska
IRIga Rusin
Iga Rusin
KMKrystian Mączka
Krystian Mączka
DGDaniel Grobecki
Daniel Grobecki
BŚBartosz Świrad
Bartosz Świrad
Schizophrenia and Alzheimer's disease are serious neurological disorders that, despite their different clinical pictures, show significant connections at the neuroanatomical, genetic, and functional levels. Research suggests that patients with schizophrenia have an increased risk of developing dementia, including Alzheimer's disease. Neuroimaging analyses indicate similarities in white matter damage, reduction in the volume of the hippocampus and prefrontal cortex, suggesting common neurodegenerative mechanisms that lead to cognitive impairment and behavioral changes. Genetic studies show a partial overlap in the polygenic risk of schizophrenia and Alzheimer's disease, especially in the genes related to neurotransmission, neuroinflammation, and synaptic function. Furthermore, the occurrence of psychotic symptoms in Alzheimer's disease may have different mechanisms than in schizophrenia, which significantly affects the effectiveness of therapy. Second-generation drugs, such as risperidone or aripiprazole, exhibit varying effectiveness depending on the neuropathological basis of psychosis, which underscores the need for individualized therapy and the search for new treatment strategies. New research directions focus on identifying neurodegenerative biomarkers and innovative therapeutic methods. There is particular hope for anti-PD-1 immunotherapy, which can modulate the inflammatory response and slow the progression of Alzheimer's disease. Additionally, the development of liquid biomarkers and advanced neuroimaging studies may enable earlier detection of pathological changes, which will allow for more effective therapeutic intervention.

18 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
IRIga Rusin
Iga Rusin
AWAmadea Wrzesińska
Amadea Wrzesińska
MKMateusz Korowacki
Mateusz Korowacki
MPMichał Przybylski
Michał Przybylski
BŚBartosz Świrad
Bartosz Świrad
JDJakub Dyczko
Jakub Dyczko
Background: Benzodiazepines remain frequently prescribed in older adults despite long-standing concerns regarding their safety. Age-related pharmacokinetic and pharmacodynamic changes, combined with increased sensitivity of the central nervous system, may amplify adverse effects. This narrative review aims to summarize current evidence on the risks associated with long-term benzodiazepine use in geriatric populations and to outline contemporary clinical recommendations for deprescribing. Results: Long-term benzodiazepine use in older adults is consistently associated with an increased risk of adverse outcomes, particularly falls and fractures, impaired cognitive function, and delirium. Evidence regarding dementia risk remains inconclusive, with observational studies suggesting a possible association, though confounding by indication cannot be excluded. Concomitant use with opioids significantly increases the risk of respiratory depression and mortality. Major clinical guidelines, including Beers Criteria and STOPP/START criteria, strongly recommend avoiding benzodiazepines in older adults, except for specific short-term indications. Deprescribing strategies, including gradual dose tapering and substitution with non-pharmacological interventions such as cognitive behavioral therapy for insomnia (CBT-I), have demonstrated effectiveness in reducing long-term use. Conclusions: Current evidence indicates that long-term benzodiazepine use in geriatric patients is associated with significant and potentially preventable harms. Despite this, inappropriate prescribing remains common in clinical practice. Structured deprescribing strategies and increased adherence to clinical guidelines are essential to improving patient safety in older populations.

9 June 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
DGDaniel Grobecki
Daniel Grobecki
KMKrystian Mączka
Krystian Mączka
BŚBartosz Świrad
Bartosz Świrad
MKMateusz Korowacki
Mateusz Korowacki
JDJakub Dyczko
Jakub Dyczko
MPMichał Przybylski
Michał Przybylski
Background: Nonunion remains a major orthopedic complication, occurring in 5–10% of fractures and drastically diminishing patients' quality of life. Traditional guidelines necessitate waiting up to nine months for a diagnosis, leading to therapeutic delays, prolonged disability, and substantial healthcare costs. This underscores the urgent need for early risk stratification. Aim: This study aims to summarize and critically evaluate the efficacy of currently available and innovative tools for the early prediction of extremity nonunion. Material and methods: A state-of-the-art narrative review was conducted. The analysis encompassed studies evaluating biological bone turnover markers, advanced imaging diagnostics, clinical scoring systems, machine learning (ML) algorithms, and smart implant technologies. Results: The isolated use of single predictive tools has significant limitations. Systemic markers reflect early fracture biology but exhibit excessive inter-individual variability. Clinical heuristics effectively exclude complications (NPV up to 100%) but inadequately identify high-risk patients (PPV ~35.5%). While ML models provide superior analytics, their current PPV of ~55% indicates a continued challenge in accurately identifying patients for early intervention. Monitoring load transfer via smart implants represents a promising parallel alternative. Conclusions: Predicting nonunion based on single modalities is insufficient. Effective prediction requires integrating multimodal diagnostics, combining comprehensive patient information with AI-driven analytics. This approach necessitates prospective, centralized databases for optimal and safe algorithm training.

6 July 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
KMKrystian Mączka
Krystian Mączka
KKKarol Kazimierczak
Karol Kazimierczak
AWAmadea Wrzesińska
Amadea Wrzesińska
DGDaniel Grobecki
Daniel Grobecki
MKMateusz Korowacki
Mateusz Korowacki
MPMichał Przybylski
Michał Przybylski
Background: Supplementation with inorganic nitrates (NO3-) and caffeine (CAF) is a common practice in competitive sports. Despite the documented ergogenic effects of both substances, their potential synergy across different exercise models remains a subject of scientific debate. Objective: The aim of this systematic review was to evaluate and compare the impact of isolated and combined CAF and NO3- supplementation on mechanical and physiological parameters in resistance and endurance tests. Methods: The review was conducted according to PRISMA guidelines by searching PubMed and Scopus databases. Experimental studies on healthy adults, published primarily between 2021 and 2026, regarding the effects of supplementation on power, strength, muscular endurance, and aerobic capacity were analyzed. Results: Nitrates improved muscular endurance 65% one repetition maximum (65% 1RM) and fatigue resistance in sprints without affecting power at maximum loads (1RM). Caffeine increased power at 75–100% 1RM (primarily in the lower body) and the number of repetitions at 65% 1RM. Co-supplementation (CAF + NO3-) showed a significant additive effect only in muscular endurance tasks. No synergy was found in time trials (TT) or cardiorespiratory parameters (VO2, heart rate). Conclusion: The combination of caffeine and nitrates is a highly effective strategy for high-volume anaerobic efforts but offers no additional benefits in traditional endurance tests. Optimizing results requires individualizing CAF dosage based on genotype and maintaining proper timing for nitrate intake.